Skip to main content
    P

    PharmaCyte Biotech Inc (PMCB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.67
    -1.01 (-15.12%)

    Market Cap: $3.77M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    PharmaCyte Biotech Inc (PMCB) Financials: Revenue, Profit and Cash Flow

    Updated Sep 14, 2026. Financial statements from company filings, amounts in US dollars.

    PharmaCyte Biotech reported revenue of $0 for the fiscal year ended Apr 30, 2026. That year, net income was -$19.42M and operating cash flow was -$5.15M. The quarter ended Jul 31, 2026 had revenue of $0 and net income of -$5.08M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Apr 2026, with an operating loss of $6.85M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Apr 2026$0N/AN/AN/AN/A
    Apr 2025$0N/AN/AN/AN/A
    Apr 2024$0N/AN/AN/AN/A
    Apr 2023$0N/AN/AN/AN/A
    Apr 2022$0N/AN/AN/AN/A
    Apr 2021$0N/AN/AN/AN/A
    Apr 2020$0N/AN/AN/AN/A
    Apr 2019$0N/AN/AN/AN/A
    Apr 2018$0N/AN/AN/AN/A
    Apr 2017$0N/AN/AN/AN/A
    Annual, fiscal years ended Apr 2017 to Apr 2026

    Income Statement

    In the fiscal year ended Apr 2026, the company posted a net loss after a profit the year before. In the quarter ended Jul 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemApr 2026Apr 2025Apr 2024Apr 2023Apr 2022Apr 2021Apr 2020Apr 2019Apr 2018Apr 2017
    Cost of revenue$0$0$0$1.23M$1.54M$1.43M$1.59M$1.56M$2.22M$1.97M
    Gross profit$0$0$0-$1.23M-$1.54M-$1.43M-$1.59M-$1.56M-$2.22M-$1.97M
    Research and development$391.30K$438.42K$407.43K$468.54K$690.94K$916.25K$301.22K$460.05K$2.00M$1.18M
    Operating income-$6.85M-$4.38M-$8.52M-$6.46M-$4.39M-$3.62M-$3.83M-$4.10M-$6.98M-$4.44M
    Net income-$19.42M$30.66M$333.76K-$4.32M-$4.24M-$3.55M-$3.83M-$4.07M-$6.83M-$4.44M
    EBITDAN/A$29.24M-$3.07M-$6.25MN/A-$3.55MN/A-$4.07M-$6.83M-$4.44M
    Fiscal years ended Apr 2017 to Apr 2026

    Quarterly

    Line itemJul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024Oct 2023
    Gross profit$0N/A$0$0$0$905.68K$0$0$0$1.09M-$620.78K-$229.16K
    Operating income-$1.01M-$2.51M-$2.12M-$1.38M-$848.30K-$1.04M-$960.25K-$1.11M-$1.27M-$3.17M-$1.87M-$1.41M
    Net income-$5.08M-$4.39M$746.86K-$7.42M-$8.36M$11.75M-$3.05M-$1.47M$23.42M$1.35M-$619.54K$2.79M
    Last 12 quarters

    Balance Sheet

    As of Apr 2026, cash and equivalents of $18.60M were 39.8% of total assets of $46.75M, against total liabilities of $11.77M.

    Annual

    Line itemApr 2026Apr 2025Apr 2024Apr 2023Apr 2022Apr 2021Apr 2020Apr 2019Apr 2018Apr 2017
    Total assets$46.75M$55.17M$59.90M$73.28M$90.62M$7.40M$6.17M$5.78M$6.41M$8.67M
    Current assets$37.42M$22.38M$50.44M$68.15M$85.49M$2.28M$1.04M$653.40K$1.28M$3.54M
    Cash and equivalents$18.60M$15.17M$50.18M$68.04M$85.40M$2.20M$894.86K$515.25K$1.06M$3.46M
    Total liabilities$11.77M$3.28M$20.39M$586.58K$704.37K$724.78K$1.08M$742.85K$644.17K$580.25K
    Short-term debtN/AN/AN/AN/AN/A$50.80K$28.92K$0N/AN/A
    Long-term debtN/AN/AN/AN/AN/AN/A$46.28K$0N/AN/A
    Shareholder equity$33.29M$51.89M$27.65M$72.69M$89.92M$6.68M$5.09M$5.04M$5.77M$8.09M
    Fiscal years ended Apr 2017 to Apr 2026

    Quarterly

    Line itemJul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024Oct 2023
    Total assets$36.71M$46.75M$55.87M$55.98M$45.11M$55.17M$43.83M$55.10M$70.19M$59.90M$71.36M$78.88M
    Total liabilities$6.90M$11.77M$16.47M$19.42M$1.52M$3.28M$3.58M$11.65M$17.15M$20.39M$22.47M$20.81M
    Cash and equivalents$17.74M$18.60M$20.17M$15.41M$13.18M$15.17M$16.38M$20.84M$32.64M$50.18M$61.21M$73.43M
    Shareholder equity$27.51M$33.29M$38.11M$35.24M$43.59M$51.89M$40.25M$43.45M$47.71M$39.51M$31.37M$36.77M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Apr 2026.

    Annual

    Line itemApr 2026Apr 2025Apr 2024Apr 2023Apr 2022Apr 2021Apr 2020Apr 2019Apr 2018Apr 2017
    Operating cash flow-$5.15M-$2.98M-$2.15M-$3.79M-$4.12M-$3.33M-$2.34M-$2.88M-$5.08M-$3.34M
    Capital expendituresN/A$4$3$0$0$0$0$0$0$0
    Free cash flowN/A-$2.98M-$2.15M-$3.79M-$4.12M-$3.33M-$2.34M-$2.88M-$5.08M-$3.34M
    Dividends paidN/A$1.13M$22.46MN/AN/AN/AN/AN/AN/AN/A
    Share repurchases$401.63K$2.54M$28.20M$13.56M$0N/AN/AN/AN/AN/A
    Investing cash flow$2.00M-$7.00M-$5.00M$0$0$0$0$0$0$0
    Financing cash flow$6.58M-$25.03M-$10.71M-$13.56M$87.31M$4.64M$2.73M$2.34M$2.68M$4.88M
    Fiscal years ended Apr 2017 to Apr 2026

    Quarterly

    Line itemJul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024Oct 2023
    Operating cash flow-$780.89K-$1.39M-$786.85K-$979.52K-$1.99M-$1.04M-$509.89K-$1.05M-$373.30K-$332.96K-$177.10K-$1.98M
    Capital expendituresN/AN/A$0$0$0$0$3$5$3$0$4$4
    Free cash flowN/AN/A-$786.85K-$979.52K-$1.99M-$1.04M-$509.90K-$1.05M-$373.30K-$332.96K-$177.11K-$1.98M
    Last 12 quarters

    Frequently Asked Questions About PMCB

    What is PharmaCyte Biotech's annual revenue?

    PharmaCyte Biotech reported revenue of $0 for the fiscal year ended Apr 30, 2026.

    Is PharmaCyte Biotech profitable?

    No. PharmaCyte Biotech reported net income of -$19.42M for the fiscal year ended Apr 30, 2026.

    How much debt does PharmaCyte Biotech have?

    The balance sheet dated Apr 30, 2026 reported cash and equivalents of $18.60M.